Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumor, Adult 1

Interventions

pembrolizumab 6Proton Therapy 3spartalizumab 2Rosuvastatin Calcium 2Paclitaxel 2Immune Checkpoint Inhibitors 2Cetuximab 2toripalimab 1sotorasib 1peposertib 1osimertinib 1necitumumab 1mirdametinib 1leronlimab 1apatinib 1amivantamab 1abemaciclib 1Valganciclovir 1Trastuzumab 1Therapeutics 1Rifampin 1Radiotherapy 1PankoMab-GEX 1Panitumumab 1Midazolam 1Metformin 1MEK inhibitor I 1Jupiter 1JPT1 protein, human 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Solid Tumor, Adult × Jupiter × Clear all
NCT04020185 2024-12-11

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

ImmuneSensor Therapeutics Inc.

Phase 1/2 Completed
40 enrolled 16 charts
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡